Introduction {#sec1}
============

Pyrrolo\[2,3-*d*\]pyrimidines (7-deazapurines)^[@ref1]^ are carba analogues of purine bases, which exert diversity of biological activities (for clarity and as reference to purines, the (7-deaza)purine nomenclature will be used in [Results and Discussion](#sec2){ref-type="other"}, but the correct IUPAC names are given in the [Experimental Section](#sec4){ref-type="other"} part). Several classes of substituted 7-deazapurine bases are inhibitors of protein kinases^[@ref2]^ and other enzymes,^[@ref3]^ resulting in therapeutically relevant biological effects. Also, many types of 7-deazapurine nucleosides were reported as anticancer agents.^[@ref4],[@ref5]^ Therefore, several synthetic approaches to diverse di-, tri-, or tetra-substituted 7-deazapurines were reported.^[@ref6]^ Introduction of a substituent onto the deazapurine scaffold can be achieved either through classical nucleophilic substitution or cross-coupling of a halogen or through C--H activation reactions.^[@ref7]^ In the recent years, our group and others reported C--H borylations,^[@ref8]^ aminations,^[@ref9]^ and phosphonations^[@ref10]^ which proceeded at position 8, whereas the Cu-catalyzed C--H sulfenylations proceeded at position 7.^[@ref11]^ On the other hand, the Ir-catalyzed C--H silylation of 6-aryl-7-deazapurines proceeded predominantly at the aryl group.^[@ref12]^ Therefore, we decided to study a complementary C--H imidation of 7-deazapurine bases to investigate the regioselectivity and possible use in the synthesis of new deazapurine derivatives for biological activity screening.

C--H imidations have been reported in the literature on several arene and heterocycle substrates using diverse reagents, such as *N*-fluorobenzenesulfonimide under Cu^[@ref13]^ or Ag catalysis,^[@ref14]^ as well as *N*-halophtalimide derivatives,^[@ref15]^ or *N*-bromosacharin^[@ref16]^ under photoredox catalysis. The most general seems to be the use of *N*-succinimidyl peroxyester (NSP)^[@ref17]^ under ferrocene catalysis. Therefore, we decided to use of the latter reagent for imidation of 7-deazapurines.

Results and Discussion {#sec2}
======================

We selected 6-phenyl-9-benzyl-7-deazapurine **1a** as a model compound to study its C--H imidation reaction with NSP^[@ref17]^**2a** under ferrocene catalysis ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The uncatalyzed reactions with 2 equiv of NSP gave only traces of the desired product **3a** (entries 1 and 2). The reaction in the presence of 5 mol % of catalyst in dichloromethane (DCM) at 50 °C gave **3a** in 12% yield (entry 3). An increase of the excess of NSP **2a** to 2.5 or 2.75 equiv resulted in increased yields of 28 and 32%, respectively (entries 4 and 5). However, further increase of NSP to 3 and 5 equiv did not bring any improvement (entries 6 and 7, respectively). Next, we decided to test the influence of ferrocene catalyst loadings, and with a lower amount of 1 mol %, we observed a decrease of the reaction yield to 23%, whereas with a higher amount of 20 mol %, the yield remained the same (entries 8 and 9). We also tried alternative catalysts, for example, a more electron-rich ferrocene, Cu(I), Mn(III), Pd(II), or Rh~2~(esp)~2~, which all worked to a certain extent, but none of them brought any improvement (entries 10--14). Also, all attempts to use other solvents or higher temperature had no positive effect (entries 15--18). Finally, by tuning the reaction concentration, we obtained a slightly better (37%) yield of desired product **3a** when performing the reaction in more diluted solution (entry 20). In most reactions, we also recovered ca. 30% of the unreacted starting material and the rest was an inseparable mixture of some highly polar compounds, presumably products of degradation. All other efforts to improve the yield by prolongation of the reaction time or by the use of additives were unsuccessful, and we used the best conditions (from entry 20) in further study.

###### Optimization of C--H Imidation Reaction of 6-Ph-9-Bn-7-Deazapurine (**1a**) with *N*-Succinimidyl Peroxyester (**2a**)[a](#t1fn1){ref-type="table-fn"}
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  entry                                **2a**, equiv   catalyst, equiv       solvent   *T*, °C   yield, %
  ------------------------------------ --------------- --------------------- --------- --------- ----------
  1                                    2.0                                   DCM       20        2
  2                                    2.0                                   DCM       50        5
  3                                    2.0             Cp~2~Fe (5%)          DCM       50        12
  4                                    2.5             Cp~2~Fe (5%)          DCM       50        28
  5                                    2.75            Cp~2~Fe (5%)          DCM       50        32
  6                                    3.0             Cp~2~Fe (5%)          DCM       50        32
  7                                    5.0             Cp~2~Fe (5%)          DCM       50        32
  8                                    2.75            Cp~2~Fe (1%)          DCM       50        23
  9                                    2.75            Cp~2~Fe (20%)         DCM       50        32
  10                                   2.75            (Ph~2~Cp)~2~Fe (5%)   DCM       50        27
  11                                   2.75            CuOAc (10%)           DCM       50        11
  12                                   2.75            Mn(OAc)~3~ (10%)      DCM       50        5
  13                                   2.75            Pd(OAc)~2~ (10%)      DCM       50        8
  14                                   2.75            Rh~2~(esp)~2~ (5%)    DCM       50        21
  15                                   2.75            Cp~2~Fe (5%)          DCE       70        27
  16                                   2.75            Cp~2~Fe (5%)          THF       50        15
  17                                   2.75            Cp~2~Fe (5%)          MeCN      80        11
  18                                   2.75            Cp~2~Fe (5%)          TFE       50        16
  19[b](#t1fn2){ref-type="table-fn"}   2.75            Cp~2~Fe (5%)          DCM       50        23
  20[c](#t1fn3){ref-type="table-fn"}   2.75            Cp~2~Fe (5%)          DCM       50        37
  21[d](#t1fn4){ref-type="table-fn"}   2.75            Cp~2~Fe (5%)          DCM       50        32

Reagents and conditions: for 0.1 mmol of **1a**, 1 mL of DCM, under Ar, 5 h.

For 0.1 mmol of **1a**, 0.2 mL of DCM.

For 0.1 mmol of **1a**, 2 mL of DCM.

1 equiv of LiO^*t*^Bu as an additive.

With optimized reaction conditions in hand, our next step was to study the scope and limitations of the method. A series of diverse 6,9-disubstituted 7-deazapurines was tested in C--H imidation reactions ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![ORTEP^[@ref18]^ view of **3a** (CCDC 1814891) shown with 50% probability displacement ellipsoids.](ao-2018-00520k_0002){#fig1}

The reactions of 6-phenyl-, 6-methyl-, and 6-chloro-substituted deazapurines **1a--c** proceeded smoothly, giving the desired products **3a--c** in acceptable 30--37% yield. Next, we tested the tolerance of other protecting groups at position 9 of 7-deazapurine, and C--H imidation proceeded smoothly with (2-trimethylsilyl)-ethoxymethyl)-protected deazapurine to give imidated product **3d** in acceptable 43% yield. Then, we tried C--H imidation of deazapurine **1a** with bulkier peroxyesters **2b** and **2c** bearing phtalimidyl and naphtalimidyl groups. These reactions proceeded reasonably well to afford desired products **3e** and **3f** in 33--35% yields. On the other hand, the C--H imidation of the 9-benzyl-7-deazaadenine derivative **1e** did not proceed, showing that the free amino group is not compatible with this reaction. Also, the attempted reaction of 9-unsubstituted 6-phenyl-7-deazapurine did not give product of imidation. We also tried other related heterocycles, that is, 9-benzyl-6-phenylpurine **4** or -6-phenyl-9-deazapurine **5**, and we did not observe any reaction. The structure of 8-imidated-7-deazapurine **3a** was confirmed by X-ray crystallography ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![Preparative C−H Imidation of 7-Deazapurines](ao-2018-00520k_0001){#sch1}

Because the succinimide or phthalimide moieties often serve as the masked amino groups, we also attempted to cleave them to access 8-amino-7-deazapurines. The hydrazinolysis of **3a** or **3e** proceeded smoothly, but we were unable to isolate desired 8-amino product **6** in pure form because of the low stability and fast decomposition ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). 8-Amino-7-deazapurine **6** was brightly fluorescent, but the fluorescence disappeared within several minutes because of the decomposition of the compound. This observation is in accordance with previously reported low stability of related 8-methylamino-7-deazapurines under acidic conditions.^[@ref9]^ Apparently, the free amino function at position 8 of 7-deazapurines makes the molecule very unstable. Analogous 2-aminoindoles were also reported to be prone to protonation, tautomerization, and auto-oxidation.^[@ref19]^

![Hydrazinolysis of 8-Imido-7-deazapurine Derivatives **3a**, **3e**](ao-2018-00520k_0003){#sch2}

Conclusions {#sec3}
===========

We explored ferrocene-catalyzed direct C--H imidations of 7-deazapurine nucleobases with several types of imidyl peroxyesters. The reactions proceeded with moderate yields, but regioselectively at position 8 of 7-deazapurines to give novel 6,9-disubstituted 8-imidyl-7-deazapurine bases. The method was applicable for 6-chloro-, 6-substituted and 9-protected deazapurines. On the other hand, the protocol was not compatible with deazaadenine, 9-unsubstituted 7-deazapurine, 9-deazapurine, and purine derivatives. The hydrazinolysis of 8-imidyl-7-deazapurines gave very unstable 8-amino-7-deazapurine, which quickly decomposed. The C--H imidation methodology complements the current toolbox of reactions for modification of the privileged deazapurine scaffold and could be used for the further synthesis of modified deazapurine heterocycles for biological activity screening.

Experimental Section {#sec4}
====================

General {#sec4.1}
-------

6-Chloro-7-deazapurine, 6-chloro-9-deazapurine, 6-chloro purine, *N*-hydroxysuccinimide, *N*-hydroxyphthalimide, *N*-hydroxy-1,8-naphthalimide, and *tert*-butyl α-bromoisobutyrate were purchased from commercial suppliers and used without any further purification. Compounds **1a--b**, **1e**, **1f**, **5**,^[@cit8a]^**1c**,^[@ref9]^ and **1d**([@cit8b]) were prepared according to reported procedures. Peroxyesters **2a--c**([@ref17]) were prepared analogously to a reported procedure starting from *N*-hydroxyimides. Dry solvents were used as received from the supplier. All reactions were carried out under an argon atmosphere. All compounds were fully characterized by NMR, and spectra were recorded with a 500 MHz (499.8 or 500.0 MHz for ^1^H and 125.7 MHz for ^13^C) spectrometer. ^1^H and ^13^C resonances were assigned based on H,C-HSQC and H,C-HMBC spectra. The samples were measured in CDCl~3~, and chemical shifts (in ppm, δ-scale) are referenced to solvent signal in CDCl~3~ \[δ (^1^H) = 7.26 ppm, δ (^1^H) = 77.0 ppm\] or in \[*d*~6~\]DMSO \[δ (^1^H) = 2.50 ppm, δ (^1^H) = 39.43 ppm\]. Coupling constants (*J*) are given in hertz. High-performance flash column chromatography purifications were performed on KP-Sil columns. High-resolution (HR) mass spectra were measured on a LTQ Orbitrap XL spectrometer using the electrospray ionization (ESI) or electron impact ionization technique. IR spectra were recorded using the KBr method (wavenumbers are given in cm^--1^). Melting points were determined on a Kofler block and are uncorrected. X-ray diffraction experiment of single crystals was carried out by monochromatized Cu Kα radiation (λ = 1.54180 Å) at 180 K.

General Procedure for C--H Imidation of 7-Deazapurines {#sec4.2}
------------------------------------------------------

7-Deazapurine **1a--d** (1.0 mmol), ferrocene (9.3 mg, 0.05 mmol), and perester **2a--c** (2.75 mmol) were placed in a vial which was purged with argon. Then, degassed DCM (20 mL) was added, and the reaction mixture was heated to 50 °C and stirred for 5 h. Upon cooling, saturated Na~2~CO~3~ (25 mL) was added, followed by extraction with EtOAc (2 × 25 mL). Combined organic layers were dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum. The crude material was purified by flash column chromatography on silica gel, eluting with hexane/EtOAc to afford the corresponding products.

### 1-(7-Benzyl-4-phenyl-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-6-yl)pyrrolidine-2,5-dione (**3a**) {#sec4.2.1}

**1a** (285 mg, 1 mmol) and **2a** (752 mg, 2.75 mmol) were used as starting compounds to give product **3a** (142 mg, 37%) as brownish crystals after chromatography (50--60% of EtOAc in hexanes) and crystallization from EtOAc/hexane. mp 176--177 °C. ^1^H NMR (500 MHz, CDCl~3~): 2.56 (vbs, 4H, CH~2~--C~4~H~4~O~2~N), 5.52 (s, 2H, CH~2~-Ph), 6.84 (s, 1H, H-5), 7.10 (m, 2H, H-*o*-Bn), 7.26--7.34 (m, 3H, H-*p*,*m*-Bn), 7.49--7.58 (m, 3H, H-*m*,*p*-Ph), 8.10 (m, 2H, H-*o*-Ph), 9.06 (s, 1H, H-2). ^13^C NMR (125.7 MHz, CDCl~3~): 28.19 (CH~2~--C~4~H~4~O~2~N), 46.11 (CH~2~-Ph), 100.59 (CH-5); 114.43 (C-4a), 126.94 (CH-*o*-Bn), 127.71 (C-6), 128.10 (CH-*p*-Bn), 128.81 (CH-*m*-Ph), 128.89 (CH-*o*-Ph), 128.92 (CH-*m*-Bn), 130.29 (CH-*p*-Ph), 135.82 (C-*i*-Bn), 137.66 (C-*i*-Ph), 151.39 (C-7a), 152.55 (CH-2), 158.34 (C-4), 174.76 (CO--C~4~H~4~O~2~N). IR (KBr): 3132, 2950, 1724, 1589, 1538, 1336, 1156, 946, 728, 692. HRMS (ESI): \[M + H\] calcd for C~23~H~19~N~4~O~2~, 383.1502; found, 383.1501.

### 1-(7-Benzyl-4-chloro-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-6-yl)pyrrolidine-2,5-dione (**3b**) {#sec4.2.2}

**1b** (243 mg, 1 mmol) and **2a** (752 mg, 2.75 mmol) were used as starting compounds to give product **3b** (102 mg, 30%) as yellowish crystals after chromatography (50--60% of EtOAc in hexanes) and crystallization from EtOAc/hexane. mp 229--230 °C. ^1^H NMR (500 MHz, CDCl~3~): 2.57 (vbs, 4H, CH~2~--C~4~H~4~O~2~N), 5.46 (s, 2H, CH~2~-Ph), 6.64 (s, 1H, H-5), 7.06 (m, 2H, H-*o*-Bn), 7.27--7.34 (m, 3H, H-*p*,*m*-Bn), 8.74 (s, 1H, H-2). ^13^C NMR (125.7 MHz, CDCl~3~): 28.21 (CH~2~--C~4~H~4~O~2~N), 46.64 (CH~2~-Ph), 99.66 (CH-5), 116.23 (C-4a), 126.89 (CH-*o*-Bn), 127.93 (C-6), 128.31 (CH-*p*-Bn), 129.01 (CH-*m*-Bn), 135.25 (C-*i*-Bn), 150.71 (C-7a), 151.79 (CH-2), 152.83 (C-4), 174.50 (CO--C~4~H~4~O~2~N). IR (KBr): 3114, 3058, 1724, 1553, 1464, 1338, 1162, 940, 701, 597. HRMS (ESI): \[M + H\] calcd for C~17~H~14~N~4~O~2~Cl, 341.0799; found, 341.0799.

### 1-(7-Benzyl-4-methyl-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-6-yl)pyrrolidine-2,5-dione (**3c**) {#sec4.2.3}

**1c** (223 mg, 1 mmol) and **2a** (752 mg, 2.75 mmol) were used as starting compounds to give product **3c** (99 mg, 31%) as a brownish solid after chromatography (80--90% of EtOAc in hexane). mp 190--200 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): 2.70 (s, 3H, CH~3~), 2.81 (s, 2 × 2H, H-4′,5′), 5.29 (s, 2H, CH~2~-Ph), 6.77 (s, 1H, H-5), 7.11 (m, 2H, H-*o*-Bn), 7.19--7.28 (m, 3H, H-*m*,*p*-Bn), 8.76 (s, 1H, H-2). ^13^C NMR (125.7 MHz, DMSO-*d*~6~): 21.12 (CH~3~-4), 28.95 (CH~2~-4′,5′), 45.17 (CH~2~-Ph), 99.24 (CH-5), 116.31 (C-4a), 127.40 (CH-*o*-Bn), 127.72 (CH-*p*-Bn), 128.32 (C-6), 128.69 (CH-*m*-Bn), 136.86 (C-*i*-Bn), 149.04 (C-7a), 151.43 (CH-2), 159.47 (C-4), 176.70 (CO-1′,3′). IR (KBr): 3138, 2926, 1727, 1589, 1462, 1359, 1162, 896, 734, 695. HRMS (ESI): \[M + Na\] calcd for C~18~H~16~N~4~O~2~Na, 343.1165; found, 343.1157.

### 1-(4-Methoxy-7-((2-(trimethylsilyl)ethoxy)methyl)-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-6-yl)pyrrolidine-2,5-dione (**3d**) {#sec4.2.4}

**1d** (279 mg, 1 mmol) and **2a** (752 mg, 2.75 mmol) were used as starting compounds to give product **3d** (172 mg, 43%) as brownish oil after chromatography (50--60% of EtOAc in hexane). ^1^H NMR (500 MHz, DMSO-*d*~6~): −0.12 (s, 9H, CH~3~Si), 0.76 (m, 2H, OCH~2~CH~2~Si), 2.90 (s, 4H, CH~2~CO), 3.33 (m, 2H, OCH~2~CH~2~Si), 4.07 (s, 3H, CH~3~O), 5.42 (s, 2H, NCH~2~O), 6.58 (s, −H, H-5), 8.53 (s, 1H, H-2). ^13^C NMR (125.7 MHz, DMSO-*d*~6~): −1.30 (CH~3~Si), 17.30 (OCH~2~CH~2~Si), 28.97 (CH~2~CO), 54.03 (CH~3~O), 65.48 (OCH~2~CH~2~Si), 70.46 (NCH~2~O), 98.45 (CH-5), 103.79 (C-4a), 126.27 (C-6), 151.29 (C-7a), 152.02(CH-2), 162.52 (C-4), 176.81 (CH~2~CO). IR (KBr): 2951, 1728, 1559, 1479, 1364, 1169, 1081, 837, 696. HRMS (ESI): \[M + Na\] calcd for C~17~H~24~N~4~O~4~NaSi, 399.1459; found, 399.1460.

### 2-(7-Benzyl-4-phenyl-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-6-yl)isoindoline-1,3-dione (**3e**) {#sec4.2.5}

**1a** (285 mg, 1 mmol) and **2b** (884 mg, 2.75 mmol) were used as starting compounds to give product **3e** (151 mg, 35%) as brownish crystals after chromatography (50--60% of EtOAc in hexanes) and crystallization from EtOAc/hexane. mp 139--140 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): 5.47 (s, 2H, CH~2~Ph), 7.03 (m, 2H, *o*-Bn), 7.12--7.16 (m, 3H, *m*-Bn, *p*-Bn), 7.23 (s, 1H, H-5), 7.56--7.64 (m, 3H, *m*-Ph, *p*-Ph), 7.93--8.01 (m, 4H, H-4′,H-5′,H-6′,H-7′), 8.16 (m, 2H, *o*-Ph), 9.01 (s, 1H, H-2). ^13^C NMR (125.7 MHz, DMSO-*d*~6~): 45.43 (CH~2~Ph), 100.96 (CH-5), 113.98 (C-4a), 124.31 (CH-4′,CH-7′), 127.21 (CH-*o*-Bn), 127.75 (CH-*p*-Bn), 128.69 (CH-*m*-Bn), 128.98 (CH-*o*-Ph), 129.29 (C-6), 129.34 (CH-*m*-Ph), 131.02 (CH-*p*-Ph), 131.63 (C-3a′,C-7a′), 135.60 (CH-5′,CH-6′), 136.71 (C-*i*-Bn), 137.02 (C-*i*-Ph), 150.89 (C-7a), 152.11 (CH-2), 156.71 (C-4), 166.75 (C=O). IR (KBr): 3120, 2944, 1723, 1574, 1512, 1328, 1101, 943, 726, 691. HRMS (ESI): \[M + H\] calcd for C~27~H~19~N~4~O~2~, 431.1502; found, 431.1503.

### 2-(7-Benzyl-4-phenyl-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-6-yl)-1*H*-benzo\[*de*\]isoquinoline-1,3(2*H*)-dione (**3f**) {#sec4.2.6}

**1a** (143 mg, 0.5 mmol) and **2c** (511 mg, 1.375 mmol) were used as starting compounds to give product **3f** (79 mg, 33%) as a yellowish solid after chromatography (50--60% of EtOAc in hexane). mp 181--182 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): 5.42 (s, 2H, CH~2~-Ph), 7.05--7.12 (m, 5H, H-*o*,*m*,*p*-Bn), 7.19 (s, 1H, H-5), 7.54--7.62 (m, 3H, H-*m*,*p*-Ph), 7.92 (dd, 2H, *J*~5′,6′~ = 8.3 Hz, *J*~5′,4′~ = 7.3 Hz, H-5′,8′), 8.18 (m, 2H, H-*o*-Ph), 8.49 (dd, 2H, *J*~4′,5′~ = 7.3 Hz, *J*~4′,6′~ = 1.3 Hz, H-4′,9′), 8.56 (dd, 2H, *J*~6′,5′~ = 8.3 Hz, *J*~6′,4′~ = 1.3 Hz, H-6′,7′), 8.98 (s, 1H, H-2). ^13^C NMR (125.7 MHz, DMSO-*d*~6~): 45.38 (CH~2~-Ph), 99.96 (CH-5), 114.10 (C-4a), 122.10 (C-3′a,9′a), 127.36 (CH-*p*-Bn), 127.51 (CH-5′,8′), 127.58 (CH-*o*-Bn), 128.32 (CH-*m*-Bn), 128.78 (CH-*o*-Ph), 128.30 (C-9′b), 129.15 (CH-*m*-Ph), 130.63 (CH-*p*-Ph), 131.45 (CH-4′,9′), 131.72 (C-6′a), 132.90 (C-6), 135.36 (CH-6′,7′), 136.75 (C-*i*-Bn), 137.47 (C-*i*-Ph), 150.79 (C-7a), 150.86 (CH-2), 156.35 (C-4), 163.80 (CO-1′,3′). IR (KBr): 3064, 2977, 2358, 1685, 1583, 1347, 1324, 1183, 782, 698. HRMS (ESI): \[M + H\] calcd for C~31~H~21~N~4~O~2~, 481.1659; found, 481.1659.

### 7-Benzyl-4-phenyl-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-6-amine (**6**) {#sec4.2.7}

**3a** or **3e** (0.2 mmol) was placed in a vial which was purged with argon, followed by addition of methanol (1 mL). Then, hydrazine hydrate (50% solution in water) (0.04 mL, 0.6 mmol) was added dropwise and stirred for 1 h. Product **6** was detectable by thin-layer chromatography, crude NMR, and HR mass spectrometry but was not isolated in pure form because of a very low stability and fast decomposition. HRMS (ESI): \[M + H\] calcd for C~19~H~17~N~4~, 301.1447; found, 301.1447.
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